tablepounding post on cycr from the ihub cytocore board:
In all my years of researching and analysing large- and mid-cap stocks and (most recently the last several years) micro-cap stocks, I have never come across an issue with the potential of CYCR. I have spent the last three weeks doing fundamental and quantitative analysis here (the cytocore website alone took up one whole weekend), and I am convinced this will be huge, and soon. The turn-around and absolved debt, the heavy insider ownership, the notes being converted into shares, the rapid addition of noted and respected members in the field to the staff and MAB, the high-quality affiliations and partnerships, the attention to shareholder value---it's astonishing. The audio interview with Dr. Weissberg, who has purchased shares on the open market, was very reassuring in the fact that he discussed his great belief in the company and it's products, and the candid way in which he discussed his preparedness to relinquish his role as CEO during the next phase to someone more adroit at the marketing end. The addition of Dr. Raab is a coup de grace. Look at his qualifications and speciality and you can see where this thing is headed. Worldwide distribution. The e2 collector can change women's lives. The products in the pipeline are equally exciting. This company is not vulnerable to sector rotation or bearish moods---as Baby-Boomers age, health concerns rise, and as the Third World becomes more industrialized, exposure to medical advances increases. Amazing potential here. Absolutely amazing potential.
AI
